Roka Bioscience (NASDAQ: ROKA) and Exact Sciences Corporation (NASDAQ:EXAS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
This is a summary of current ratings and target prices for Roka Bioscience and Exact Sciences Corporation, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Exact Sciences Corporation||0||5||8||0||2.62|
Roka Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 952.63%. Exact Sciences Corporation has a consensus price target of $50.77, indicating a potential downside of 13.76%. Given Roka Bioscience’s stronger consensus rating and higher possible upside, research analysts plainly believe Roka Bioscience is more favorable than Exact Sciences Corporation.
Volatility and Risk
Roka Bioscience has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Exact Sciences Corporation has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
This table compares Roka Bioscience and Exact Sciences Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Exact Sciences Corporation||-60.71%||-30.32%||-27.37%|
Insider and Institutional Ownership
65.6% of Roka Bioscience shares are owned by institutional investors. Comparatively, 85.7% of Exact Sciences Corporation shares are owned by institutional investors. 29.2% of Roka Bioscience shares are owned by company insiders. Comparatively, 4.0% of Exact Sciences Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Roka Bioscience and Exact Sciences Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Roka Bioscience||$7.24 million||0.66||-$30.78 million||($8.80)||-0.11|
|Exact Sciences Corporation||$99.38 million||70.92||-$167.21 million||($1.16)||-50.75|
Roka Bioscience has higher revenue, but lower earnings than Exact Sciences Corporation. Exact Sciences Corporation is trading at a lower price-to-earnings ratio than Roka Bioscience, indicating that it is currently the more affordable of the two stocks.
Exact Sciences Corporation beats Roka Bioscience on 8 of the 13 factors compared between the two stocks.
Roka Bioscience Company Profile
Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Receive News & Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.